IL28B基因多态性及其表达与慢性乙型肝炎感染转归的相关性研究

Correlation between genetic variation and expression of IL28B with prognoses of chronic hepatitis B infection patients

目的探讨IL28B基因多态性(SNPs)及其血清IFN-λ3水平与聚乙二醇干扰素联合利巴韦林治疗乙型肝炎疗效的相关性。方法选择2013年6月-2013年12月100例HBeAg阳性慢性乙型肝炎(CHB)患者,给予聚乙二醇化干扰素α(Peg-INF-α)联合利巴韦林规范治疗48周后,分为应答组48例及非应答组52例,分析患者IL28BSNPs、HBV基因型、HBsAg、HBeAg及IFN-λ3表达与患者治疗疗效的关系。结果 IL28B基因rs12979860位点CC型和CT+TT型的比例在应答组和非应答组差异较大,差异有统计学意义(χ2=8.253,P<0.05);应答组患者治疗48周后HBV-DNA、HBsAg、HBeAg水平均低于非应答组,差异均有统计学意义(P<0.05);应答组患者血清IFN-λ3水平高于非应答组,差异有统计学意义(P<0.05);在应答组及非应答组中,IL28B基因CC型患者48周IFN-λ3血清学表达水平高于CT+TT型,差异均有统计学意义(P<0.05)。结论 IL28BSNPs及其血清IFN-λ3水平可能影响Peg-INF-α联合利巴韦林治疗的应答反应,对CHB患者治疗疗效有一定预测价值。

OBJECTIVE To explore the relationship between the single nucleotide polymorphisms（SNPs）of IL28 B gene and the serum levels of IFN-λ3with polyethylene glycol interferon combined with ribavirin treatment to chronic hepatitis B patients.METHODS A total of 100 HBeAg positive patients with chronic hepatitis B in our hospital from Jun.2013 to Dec.2013 were selected and treated with peg-interferonα-2a（Peg-INF-α）combined with ribavirin.After 48 weeks of treatment,all the patients were divided into responsive group（n=48）and non-responsive group（n=52）.The relationship among IL28 Bpolymorphisms,HBV genotype,hepatitis B s antigen（HBsAg）levels,HBeAg levels,IFN-λ3levels and the response to the treatment were analyzed.RESULTS The distribution frequencies of IL28 Brs 12979860CC and CT＋TT genotypes showed significant differences between the responsive group and nonresponsive group（χ2=8.253,P〈0.05）.The levels of HBV-DNA、HBsAg and HBeAg for 48 weeks in responsive group were significantly lower than nonresponsive group,and the difference was statistically significant（P〈0.05）.The levels of IFN-λ3for 48 weeks in responsive group were significant higher than nonresponsive group（P〈0.05）.The levels of IFN-λ3of IL28 Bpolymorphisms CC genotype were significantly higher than CT＋TT genotype（P〈0.05）.CONCLUSIONThe levels of IL28 BSNPs and IFN-λ3would be possible to influence the response of peg-interferonα-2acombined with ribavirin,which has certain predict value for the treatment in CHB patients.